Last reviewed · How we verify
Halfan (HALOFANTRINE)
Halofantrine (Halfan), marketed by GSK, is an antimalarial drug specifically indicated for the treatment of falciparum malaria. Its key strength lies in its unique mechanism of action, which disrupts the parasite's cell membrane potential by blocking potassium channels, setting it apart from other antimalarials. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | HALOFANTRINE |
|---|---|
| Sponsor | GSK |
| Drug class | Antimalarial |
| Target | Potassium voltage-gated channel subfamily H member 2 |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
| First approval | 1992 |
Approved indications
- Falciparum malaria
- Vivax malaria
Common side effects
Drug interactions
- High Risk QT Prolonging Agents
- bedaquiline
Key clinical trials
- Dental Biofilm Control During Orthodontic Treatment (PHASE3)
- A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals (PHASE1,PHASE2)
- Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) (PHASE3)
- Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People (PHASE4)
- Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects (PHASE1)
- Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects (PHASE1)
- Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia. (NA)
- Combined Procedures in the Treatment of Severe Acne Scars (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Halfan CI brief — competitive landscape report
- Halfan updates RSS · CI watch RSS
- GSK portfolio CI